

# **Annex B - Statement on the safety of Titanium Dioxide (E171) as a Food Additive**

## **In this guide**

### [In this guide](#)

1. [Executive Summary - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
2. [Introduction - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
3. [Titanium Dioxide - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
4. [Absorption, Distribution, Metabolism and Excretion \(ADME\)](#)
5. [Review of toxicity for endpoints identified by the COT](#)
6. [Reproductive and Developmental Toxicity - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
7. [Aberrant Crypt Foci \(ACF\) as a potential biomarker for carcinogenicity](#)
8. [Genotoxicity - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
9. [Inflammation and Immunotoxicity - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
10. [Neurotoxicity - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
11. [Establishment of a Health-Based Guidance Value \(HBGV\) - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
12. [Exposure Assessment - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
13. [Assumptions and uncertainties - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
14. [Risk characterisation - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)

15. [Conclusions - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
16. [Abbreviations Table - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
17. [References - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
18. [Annex A - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
19. [Annex B - Summary table of studies](#)
20. [Annex C - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)
21. [Annex D - Statement on the safety of Titanium Dioxide \(E171\) as a Food Additive](#)

## **Absorption, Distribution, Metabolism and Excretion (ADME) - E171 animal studies**

| Reference | TiO <sub>2</sub><br>characterisation study e.g.,<br>OECD/GLP | Quality of<br>study e.g.,<br>OECD/GLP | Method<br>and<br>duration of<br>dosing | Study<br>methodology to<br>include species, Results<br>numbers,<br>controls, |
|-----------|--|---------------------------------------|--|--|
|-----------|--|---------------------------------------|--|--|

|                                    |             |   |  |   |
|------------------------------------|-------------|---|--|---|
| <p><b>Bettini et al., 2017</b></p> | <p>OECD</p> | <p>1) E 171, anatase, 20–340 nm (118 nm) (TEM); 44.7% particles 100 nm;</p> <p>2) TiO<sub>2</sub> NPs (NM-105), anatase/rutile, 15–24 nm.</p> | <p>Series One: rats (n = 10 rats/group) dosed daily by intragastric gavage (200 µ L) with TiO<sub>2</sub> NM-105, E171 (10 mg/kg of BW/day) or water for 7 days.</p> <p>Tissue imaging, flow cytometry and cytokine assays, tissue inflammation and gut permeability measurements were conducted.</p> <p>Series Two: rats (n = 11 to 12 per group) were treated or not with 1,2-dimethylhydrazine (DMH) to induce colon carcinogenesis and exposed to E-171 at 200 µ g or 10 mg/kg of BW/day via drinking water for 100 days (with or without DMH treatment).</p> <p>Series Three Dosage: No</p> | <p>Titanium was detected in immune cells of Peyer's patches. Dendritic cell percentages increased after exposure. No effect was observed after 7 days.</p> <p>No effects were observed in spleen.</p> <p>Regulatory T-cells and T-helper cells were significantly decreased after exposure at 100 days. Rats exposed to E-171.</p> <p>Stimulation of immune cells isolated from Peyer's patches had a decrease in T-helper (Th) cytokine secretion. Splenic Th cytokine responses increased.</p> <p>With exposure to TiO<sub>2</sub> NP there was an observed increase in dendritic cell percentages.</p> |
|                                    |             |   |  | <p>Tissue imaging, flow cytometry and cytokine assays, tissue inflammation and gut permeability measurements were conducted.</p> <p>Series Two: rats (n = 11 to 12 per group) were treated or not with 1,2-dimethylhydrazine (DMH) to induce colon carcinogenesis and exposed to E-171 at 200 µ g or 10 mg/kg of BW/day via drinking water for 100 days. Control animals (n = 12) received water only.</p> <p>Flow cytometry and cytokine assays were</p>   |
|                                    |             |   |  | <p>Titanium was detected in immune cells of Peyer's patches. Dendritic cell percentages increased after exposure. No effect was observed after 7 days.</p> <p>No effects were observed in spleen.</p> <p>Regulatory T-cells and T-helper cells were significantly decreased after exposure at 100 days. Rats exposed to E-171.</p> <p>Stimulation of immune cells isolated from Peyer's patches had a decrease in T-helper (Th) cytokine secretion. Splenic Th cytokine responses increased.</p> <p>With exposure to TiO<sub>2</sub> NP there was an observed increase in dendritic cell percentages.</p> |
|                                    |             |   |  | <p>Titanium was detected in immune cells of Peyer's patches. Dendritic cell percentages increased after exposure. No effect was observed after 7 days.</p> <p>No effects were observed in spleen.</p> <p>Regulatory T-cells and T-helper cells were significantly decreased after exposure at 100 days. Rats exposed to E-171.</p> <p>Stimulation of immune cells isolated from Peyer's patches had a decrease in T-helper (Th) cytokine secretion. Splenic Th cytokine responses increased.</p> <p>With exposure to TiO<sub>2</sub> NP there was an observed increase in dendritic cell percentages.</p> |

**Talamini  
et al.,  
2019**

E171 (35% nano determined by TEM), 99.3% pure anatase,  $201.2 \pm 8.5$  nm in suspension (NTA).

No sonification or deagglomeration to simulate realistic conditions.

This work was reviewed by the Institute for Pharmacological Research Mario Negri IRCCS Animal Care and Used Committee (IACUC) and then approved by the Italian National Institute of Health (code:42/2016-PR).

Treatments were given 3 days per week for 3 weeks for a total of 9 treatments in 21 days. Average daily dose of  $\sim 2$  mg/kg bw.

Treatments were dripped slowly into the mice's mouths, allowing each drop to be swallowed.

NFR male mice (22/group) were administered either water (control) or 5 mg/kg bw E171 suspended in water.

Ti concentrations in tissues were determined by single particle ICP-MS analysis.

Ti concentration in the liver was  $0.57 \mu\text{g/g}$  and large ( $1.07 \pm 0.1$  tissue) were significant in treated compared to controls.

Ti concentration in the brain, kidney, and were below quantification ( $0.03 \mu\text{g/g}$ ).

Ti concentration in lungs, stomach, intestine were not statistically significant in treated and control mice.

**Riedle et al., 2020** E171, anatase, 119 nm.

N/A

Mice were exposed to 0, 1, 10, or 100 mg/kg bw/d E171 via the diet for 6, 12 and 18 weeks.

Mice were divided into 4 groups of 18 and given 0, 6.25, 62.5, or 625 mg/kg diet (equivalent to approximately 0, 1, 10, or 100 mg/kg bw). Then 6 mice per group were euthanized at 6, 12 and 18 weeks.

No evidence of gross alterations in immune-cell physiology or inflammatory responses at doses up to 625 mg/kg bw/d diet.

Authors demonstrated uptake by peritoneal patches, with the delivery of particles.

Presence of particles confirmed by reflectance confocal microscopy quantification of particles completely.

Weak signals observed at the base of peritoneal patches at mid-doses. Signals observed at the highest dose indicating a dose-response.

**Comera  
et al.  
2020**

Food grade TiO<sub>2</sub>  
(E171) 95%  
anatase.

European  
legislation  
(Council  
Directive  
2010/63/UE)  
and French  
Decree  
2013-118-  
compliant.

Mice (4 per  
group).

Dosage:  
single dose  
(200 µl) of  
either

E171 at 40  
mg/kg of  
body weight  
(BW) or 200  
µl of vehicle  
(water) by  
intragastric  
gavage.

In addition,  
in some  
experiments,  
the gavage  
solution  
from  
sonicated  
E171  
particles was  
equilibrated  
in 30% corm  
oil and  
vortexed  
before oral  
delivery.

Adult C57BL/6  
mice (12–18  
weeks).

Animals were  
terminated at 2,  
4, 8, and 24 hours  
to recover the  
intestine.

Small intestine:  
TiO<sub>2</sub> absorption  
peaked at 4 h in the  
jejunal and ileal  
villi and returned  
to basal level by 8 h and undetectable  
at 4 h but still  
present at 24 h in  
the jejunal  
patches.

Colon: Low  
absorption.

Blood: TiO<sub>2</sub>  
particles were  
detected in the  
8-hours post  
treatment.

30 minute  
exposure to  
the presence of  
absence of  
pharmacological  
inhibitors of  
paracellular  
junction (ZO-2  
permeability  
absorption).  
jejunal villi  
decreased  
(p 0.001 vs  
control) in the  
presence of  
triaminopurine.

Other inhibitors  
had no significant  
effect.

Absorption of  
goblet cells  
associated with

|                                    |   |     |   |  |  |
|------------------------------------|---|-----|---|--|--|
| <b>Dudefoi<br/>2017b</b>           | Food-grade TiO <sub>2</sub><br>(E171-1, 17% NPs<br>and 100% anatase and<br>E171-6a).                      | N/A | Dosage:<br>100-250<br>ppm.  | Method: A defined<br>model intestinal<br>bacterial<br>community. | At these low<br>concentrations, no<br>impact on<br>production of<br>only a minor<br>on fatty acid<br>profiles was<br>observed<br>limited effect on<br>bacterial<br>community   |
| <b>Proquin<br/>et al.<br/>2018</b> | E171 in<br>combination with<br>azoxymethane<br>(AOM)/dextran<br>sodium sulphate<br>(DSS) vs E171<br>only. | N/A | Dosage: 5<br>mg/kg bw<br>per day of<br>E171 by<br>gavage for<br>2, 7, 14, and<br>21 days. | BALB/c mice.   | E171 induced<br>downregulation<br>genes involved<br>the immune<br>system with<br>indicative of<br>impairment<br><br>Additional<br>signalling<br>involved in<br>variety of<br>cancer including<br>colorectal<br>were modulated<br>and effects<br>observed<br>indicated<br>potential<br>association<br>oxidative |

**Jensen et al. 2019**

Vegetable carbon (E153) and food-grade titanium dioxide (E171), mean TiO<sub>2</sub> particle size of 270 nm.

N/A

Dosage: 10 weeks by oral gavage once a week.

Rats.

TiO<sub>2</sub>-only

Decreased expression of protein TJ observed in rats only compared to E171 (5 mg/kg/week) shorter lung telomeres

This study found no oxidative damage in liver or lung and no changes in DNA repair of oxidative damage in lung.



4 different food  
**Farrell TP** grade TiO<sub>2</sub> test  
**and** items containing GLP-compliant,  
**Magnuson** a range of particle OECD TG 41.  
**B. (2017).** sizes and  
morphologies.

Dosage:  
Four grades of TiO<sub>2</sub> (200 ppm) or control (0 ppm) via the diet for 7 days followed by a control diet for 1, 24, or 72 hours.  
Male and female Sprague-Dawley rats were given TiO<sub>2</sub> by the diet equivalent to 30 mg/kg bw/day for 7 days.  
Animals were then terminated post-feeding at 1, 24 and 72 hours.

Ti in kidney and muscle below LOD mg/kg ww

Ti in tissue above LOD 0.1-0.3 mg

Ti in blood 0.04 mg/L samples.

Ti in urine equal to 2 dose/L and LOQ.

Ti in faeces found to be main route of excretion.

No difference in absorption found between different grades of TiO<sub>2</sub>.

## Absorption, Distribution, Metabolism and Excretion (ADME) - non-E171/Nanoparticle animal studies

| Reference | TiO <sub>2</sub><br>characterisation study | Quality of<br>study e.g.,<br>OECD/GLP | Method and<br>duration of<br>dosing | Study<br>methodology to<br>include species,<br>numbers,<br>controls, | Results |
|-----------|--|---------------------------------------|-------------------------------------|--|---------|
|-----------|--|---------------------------------------|-------------------------------------|--|---------|

**Warheit,  
Boatman  
and Brown,  
2015**

1)  
anatase/rutile  
(89/11%) (uf-1),  
d50=43 nm  
d50=23 nm.

Methods: XSDC  
and TEM  
respectively  
Shape: Irregular.

2) anatase  
(100% nano) (uf-  
2) d50= 42 nm  
d50=19 nm.

Methods: XSDC  
and TEM  
respectively.

Shape: Irregular.

3) rutile (100%  
nano) (uf-3),  
d50=47 nm  
d50=22 nm  
Methods: XSDC  
and TEM  
respectively.

Shape: rod-like.

4) anatase  
(27% nano) (pg-  
1), d50=153 nm  
d50=120 nm  
Methods: XSDC  
and TEM

OECD  
Guideline  
414.

Sterile water-  
based TiO<sub>2</sub>  
sample  
formulations  
were  
administered  
by oral  
gavage to  
time-mated  
rats from the  
time of  
approximate  
implantation  
until the day  
prior to  
expected  
parturition.

Dose levels:  
0, 100, 300 or  
1,000 mg/kg  
bw per day.

Dosage  
volume: 5  
ml/kg bw per

Three studies  
(Group size n=22):  
Time-mated  
pregnant  
Sprague-Dawley  
rats, (Crl:CD(SD))  
exposed to TiO<sub>2</sub> (uf-  
1, uf-3 and pg-1) by  
gavage on  
Gestational Days  
6-20.

Three additional  
studies (Group size  
n=22-23) pregnant  
Wistar rats exposed  
to TiO<sub>2</sub> (uf-2 and  
pg-2) by gavage  
from Gestational  
Days 5 to 19.

Necropsy:

- Gross examination of the dam,
- Counting of corpora lutea,
- Implantation sites,
- Resorptions,
- Live and dead fetuses,
- Fetal sex,

At 1,000  
1/kg per  
mean fe  
ratio an  
means f  
and fem  
fetuses

were  
statistic  
significa  
differen  
the con  
group m

Mean m  
fetuses:

Mean m  
fetuses  
group: 5

Test fac  
historica  
group d  
range: 5  
7.4.

Mean fe  
fetuses:

Mean fe  
fetuses  
group: 6

Test fac  
historica  
group d  
range: 5  
8.3.

Mean fe  
ratio of  
1,000 m  
bw per  
group: 6  
(male)

**Tassinari et al., 2014**

TiO<sub>2</sub> nanoparticles (anatase, primary size 25 nm, BET surface area 45-55 m<sup>2</sup>/g, purity 99%).

All experiments on animals were performed according to the European Community Council Directive 86/609/EEC (EEC 1986).

TiO<sub>2</sub> nanoparticles were administered by oral gavage over 5 consecutive days at a dose of 0, 1, 2 mg/kg body weight per day.

Sprague-Dawley rats were divided into 3 treatment groups (7 rats/sex/group). Treatment groups were high dose (2 mg/kg bw), low dose, (1 mg/kg bw), and controls (CTRL) (vehicle only (distilled water)).

In the high-dose treatment group, significant increases in total T<sub>4</sub> levels were found in males (0.036 ± 0.008 μg weight; 0.05) and ovaries (0.07 vs. 0.04 μg weight; 0.01).

Sex-related histological alterations were observed in both doses in thyroid, adrenal medulla, adrenal cortex (female), ovarian granulosa without toxicity.

Altered thyroid function indicated reduced T<sub>4</sub> (males). Testosterone levels in high-dose males and decreased

**Ammendolia  
et al. 2017**

Nano-sized  
titanium dioxide (  
anatase, primary  
size 25 nm, BET  
surface area  
45-55 m<sup>2</sup>/g,  
purity 99%).

N/A

TiO<sub>2</sub> NPs at 2  
mg/kg bw per  
day for five  
days in male  
and female  
rats.

N/A

Nanopa  
depositi  
intestin  
and incr  
serum  
testoste  
levels. T  
was no  
of oxida  
stress o  
alteratio  
concent  
of TiO<sub>2</sub>  
howeve  
treatme  
associat  
testoste  
Insulin-I  
Growth  
showed  
increase  
prolifera

**Geraets et al. 2014**

TiO2 NPs (sizes NM-100, NM-101, NM-102, NM-103, and NM-104) with N/A differing particle sizes and structure.

Dosage: Oral and intravenous administration of a single or five repeated doses.

TiO2 nanoparticle kinetics were investigated using intravenous injection and oral dosing in rats. For orally dosed rats, liver, spleen and lymph nodes were targeted for analysis.

Following exposure, levels in liver and spleen were on occasion above t and was detected lymph n low leve

Following intraven exposure distribu observe all tissu kidney, spleen, brain, th and reprodu organs v liver ide as the r target.

Recover hours p exposure 64-95% 108% respect male an female

The ma relative decreas TiO2 up days po exposure 26%.

**Hendrickson et al. 2016** 2 test items TiO<sub>2</sub> NPs (5-10 nm and 20-25 nm respectively). N/A

Dosage:  
Intragastric administration of TiO<sub>2</sub> NPs (1 of 2 test items) for 28 days at a dose of 250 mg/kg of body weight per day.

GIT and secondary organ translocation were size dependent

Larger nanoparticles exposure showed deposition in liver, kidney, spleen, small intestine (0.01– 0.05 µg/g of organ)

Smaller nanoparticles exposure resulted in deposition in brain, lung, heart, liver, kidneys, small intestine, testicles, blood (0.004– 0.01 µg/g of organ)

**Hendrickson  
et al. 2020**

TiO<sub>2</sub> NPs

N/A

Dosage: A  
single dose  
suspension of  
TiO<sub>2</sub> NPs (250  
mg/kg of body  
weight).

Model: A  
Physiological model  
designed to mimic  
the intestinal lumen  
of an experimental  
animal.

TiO<sub>2</sub> NP  
found in  
small in  
mucosa  
and sple

TiO<sub>2</sub> NP  
resulted  
differen  
changes  
cellular  
ultrastru  
in the  
endoplas  
reticulu  
mitocho  
extensio  
the peri  
spaces  
caused  
like stru  
to appe

The mo  
sensitiv  
was not  
the sple



**Kreyling et al. 2017a**

TiO<sub>2</sub> anatase NPs.  
Median agglomerate size: 70 nm.  
N/A

Dosage: 40–400 µg/kg bw single intravenous dose in aqueous suspension.

Female Wistar rats. Clearance and biokinetics were observed from 1-hour post-dosage to 4 weeks.

Highest accumulation occurred in liver after 1 day (95% of dose) then the spleen (10% of carcass) and skeleton (0.4%). NPs were detected in other organs at levels lower than the

TiO<sub>2</sub> NP blood dose quickly after ex

Organs tissue N were sta day-28.

**Kreyling et al. 2017b**

TiO<sub>2</sub> NPs.

N/A

Dosage: Oral  
dosage of a single dose of an aqueous TiO<sub>2</sub> NP suspension at 30–80 µg/kg bw.  
Female Wistar-Kyoto rats.  
Assessed 1 h, 4 h, 24 h and 7 days post-oral exposure.

0.6% of administered dose passed gastro-intestinally after 1 h

0.05% of dose was distributed to the body after 7 days distributed across the following organs:

liver (0.29 ng/g), lungs (0.29 ng/g), kidney (0.29 ng/g), brain

(0.36 ng/g), spleen (0.36 ng/g), uterus (0.55 ng/g), bone debris (0.98 ng/g)

Faecal excretion was confirmed after 4–7 days

|                      |           |     |  |  |  |   |
|----------------------|-----------|-----|--|--|--|---|
| Sadiq et al.<br>2012 | TiO2 NPs. | N/A | <p>Dosage: 1)<br/>Intravenous<br/>0.5, 5.0, and<br/>50 mg/kg<br/>TiO2 NPs.</p> <p>2)<br/>Intravenous<br/>three daily<br/>doses of 50<br/>mg/kg TiO2<br/>NPs Ti levels<br/>in bone<br/>marrow<br/>measured<br/>after 4, 24,<br/>and 48 hours<br/>of the last<br/>treatment.</p> | 6-7-week-old male<br>B6C3F1 mice.  | In vivo micronucleus<br>and Pig-a<br>(phosphatidylinositol<br>glycan, class A<br>gene) mutation<br>assays using TiO2<br>NPs to evaluate<br>genotoxicity. | Blood re<br>No incre<br>Pig-a m<br>frequen<br>%MN-R   |
|                      |           |     |  |  | Blood: Samples<br>taken one day<br>before the<br>treatment and on<br>Day 4, and Weeks 1,<br>2, 4, and 6 after the<br>beginning of the<br>treatment.      | Tissue r<br>Ti NPs p<br>at 4 hou<br>exposur<br>%RETs v<br>reduced<br>treated<br>on Day<br>depend<br>which s<br>cytotox<br>TiO2-NP<br>bone m |
|                      |           |     |  | Pig-a mutant<br>frequencies were<br>determined at Day<br>-1 and Weeks 1, 2,<br>4 and 6, percent<br>micronucleated-<br>reticulocyte<br>frequencies were<br>measured only on<br>Day 4. | No evid<br>genotox   |   |

## Absorption, Distribution, Metabolism and Excretion (ADME) - E171 and non-E171/Nanoparticle Human Studies

| Reference               | TiO <sub>2</sub> characterisation                               | Quality of Method study e.g., OECD/GLP of dosing                   | Study methodology to include species, numbers, controls,   | Results  |
|-------------------------|---|--|--|--|
| <b>Pele et al. 2015</b> | Pharmaceutical/food grade TiO <sub>2</sub> , anatase, 50-250nm. | This study was conducted based on ethical approval under EC01/037. | Dosage: A single dose of 100 mg TiO <sub>2</sub> .<br><br>Test subjects: Humans with normal intestinal permeability.<br>Blood samples were collected at between 0.5 to 10 h post-oral exposure.<br>Blood samples were analysed for visual TiO <sub>2</sub> reflective particles using dark field microscopy. | Early absorption occurred by 2 hours with a peak maximum at 6 hours.<br>Following oral dosing. This mirrors the results of a previous study by Bockmann et al (2000) which the authors were attempting to replicate. |

**Guillard  
et al.  
2020**

Basal Ti level in  
human placenta  
study.

N/A

TiO<sub>2</sub> with 55% NPs,  
20 to 440 nm.

Samples  
were  
taken of  
placenta  
and

meconium TiO<sub>2</sub> in human  
from placentas was  
human analysed by  
babies ICP-MS and  
(n=22) STEM coupled  
and to EDX  
tested for spectroscopy.  
TiO<sub>2</sub> and  
other  
metals  
and trace  
elements.

All placenta  
contained  
TiO<sub>2</sub> at 0.01  
to 0.48 mg/kg  
of tissue with  
the majority  
below 100nm  
in size (over  
50%).

Meconium  
samples also  
contained  
TiO<sub>2</sub> between  
0.02-1.5  
mg/kg.

|                            |   |     |     |   |  |
|----------------------------|---|-----|-----|---|--|
|                            |   |     |     |   | 7 of the 15 livers sampled contained TiO <sub>2</sub> and 13 of 15 of spleen samples contained the same. |
|                            |   |     |     |   | Particle sizes respectively for liver and spleen:  |
|                            |   |     |     |   | 85-550nm and 85-720nm with 24% 100 nm in size.   |
| <b>Heringa et al. 2018</b> | Post-mortem analysis of human liver and spleen TiO <sub>2</sub> analysis. | N/A | N/A | High resolution ICP-MS was used to detect TiO <sub>2</sub> in the liver and spleen in 15 deceased humans (9 female and 6 male). | Particle mass concentration for liver and spleen respectively:   |
|                            |   |     |     |   | To 0.3 mg titanium/kg tissue and 0.01 to 0.4 mg titanium/kg tissue.                                      |
|                            |   |     |     |   | Average concentration in liver and spleen samples:   |
|                            |   |     |     |   | 40 ng/g and 80 ng/g.   |

**Peters et al. 2020**

Postmortem tissue analysis of deceased persons for the presence of TiO<sub>2</sub>.

Detected particle sizes were in the range of 50–500 nm, with a mode of 100–160 nm.

15 humans sampled, 8 female and 7 male aged 64–98 years.

Postmortem liver, spleen, kidney, jejunum and ileum were sampled.

Findings of between 0.01 to 2.0 mg Total Ti/kg with median values (mg Ti/kg):

Liver = 0.02,

Spleen = 0.04,

Kidney = 0.05,

Jejunum = 0.13,

Ileum = 0.26.

Particulate TiO<sub>2</sub> were observed from 0.01 to 1.8 mg Ti/kg with median values (mg Ti/kg):

Liver = 0.02,

Spleen = 0.02,

Kidney = 0.03,

Jejunum = 0.08,

Ileum = 0.25.

Particulate TiO<sub>2</sub> accounted for 80% of the

# Aberrant Crypt Foci (ACF) as a marker for carcinogenicity

| TiO2 | Quality of study<br>e.g.,<br>OECD/GLP | Method and<br>duration of dosing | Study methodology to<br>include species, numbers,<br>controls, | Results |
|------|---------------------------------------|----------------------------------|--|---------|
|------|---------------------------------------|----------------------------------|--|---------|



E-171  
consum  
not alte  
mediate  
mechar  
immune

Dietary  
did not  
inflamm  
periphe  
the GI t

Six-week-old male

Wistar Han IGS  
(CrI:WI (Han))  
rats.

An incre  
observe

relative

weight

Test material:  
Food grade  
sample E-171.

mg E-1

per day

compar

Different grades  
of commercially-  
available E-171

initiated

and an

in IL-17

were averaged to  
produce the test  
material supplied.

(22.4 m

171/kg

day + D

Test material was  
added to feed.

IL-12p7

plasma

E 171/k

day + D

with no

related

Two feed batches:  
batch one was fed  
throughout the 7-

day study and  
through week 10  
of the 100-day

No char

observe

spleen

cellular

study. Batch two  
was fed post-

week 10 of the  
100-day study.

No char

observe

percent

7-day study: 4  
groups of 5  
animals  
(randomised

CD103-

CD4+ T

cells or

**Akagi et al., 2023 - 28 Day Study**

6 nm TiO<sub>2</sub> nanoparticles.

N/A

5 female and 5 male F344/DuCrI CrIj rats.

TiO<sub>2</sub> NPs with a crystallite size of 6 nm were examined in male and female F344/DuCrI CrIj rats by repeated oral administration of 10, 100, and 1000 mg/kg bw/day (5/sex/group) for 28 days.

No mor  
observe  
group, a  
treatme  
related  
effects  
observe  
weight,  
urinalys  
haemat  
serum  
biochem  
organ w  
Histopa  
examin  
reveale  
particle  
deposit  
yellowis  
material  
particle  
observe  
gastroin  
lumen v  
found in  
nasal co  
epitheli  
stromal  
the 28-  
study.  
Overall,  
effects  
observe  
repeate  
adminis  
TiO<sub>2</sub> wi  
crystall  
6 nm at  
1000 m  
bw/day  
regardi  
general

| Reference                 | TiO <sub>2</sub> characterisation  | Quality of study e.g., OECD/GLP | Method and duration of dosing   | Study methodology to include species, numbers, controls,                             | Results   |
|---------------------------|--|---------------------------------|---|--|---|
| <b>Donner et al. 2016</b> | One of three pigment-grade or one of three ultrafine /nanoscale anatase and/or rutile TiO <sub>2</sub> test materials. | OECD 474 Guidelines.            | Dosage: Single oral gavage doses of 500, 1000 or 2000 mg/kg body weight with negative (water) and positive controls (cyclophosphamide). | Male and female rats.<br><br>Blood samples were collected 48 and 72 h post-exposure. | There was no relevant increase in micronucleated RET frequency in any TiO <sub>2</sub> exposed rats at either point at the dose level tested.<br><br>All tests were negative for in vivo genotoxic effects, significant or liver enzyme increases following exposure to the highest dose. |

## Reproductive toxicity

| Reference | TiO <sub>2</sub> characterisation | Quality of study e.g., OECD/GLP | Method and duration of dosing | Study methodology to include species, numbers, controls, | Results |
|-----------|-----------------------------------|---------------------------------|-------------------------------|--|---------|
|-----------|-----------------------------------|---------------------------------|-------------------------------|--|---------|

Results:

F0 - Dose-dependent marginal increase in blood and concentrations in rats dosed 1000 mg/kg bw/day.

No test item-related effects on sexual function or fertility in males or females. test item-related pre- or post-loss observed.

No test item-related thyroid hormone or haematological effects.

No test item-related differences in splenic lymphocyte subpopulation distribution.

No test item-related changes related to histopathological examination including testis and epididymis and intestines.

|  |   |                          |  |  |   |
|--|---|--------------------------|--|--|---|
| <b>Leuschner, 2020 - Satellite study</b> |   |                          |  |  | No test item related effects on behaviour or external appearance.                 |
|  |   |                          |  |  | No test item related thyroid hormone effects.                                     |
|  |   |                          |  |  | No test item related effects on body weight, food consumption, water consumption. |
|  |   |                          |  |  | No test item related effects on haematology and                                   |
|  |   |                          |  | CD® (Sprague Dawley) IGS Rat (CrI:CD(SD)).   | biochemical parameters, urinalysis.   |
|  | Test substance: Anatase E-171, 51% of particles 100 nm. | OECD Test Guideline 443. | F0 satellite group: 0, 100, 300, and 1000 mg/kg bw/day over 10 weeks (prior to mating and up to the end of weaning periods). | F0 satellite group - 30 male, 30 female per group + additional 40 (20 male, 20 female) for use as an F1 generation of satellite animals to be used as the positive control group in the KLH-assay (?). | No test item related effects on thyroid sexual hormones or sperm.                 |
|  | Dietary particle size: 31-43% of particles 100 nm.      |                          |  |  | No test item related changes in bone mass or organ weights.                       |
|  |   |                          |  | Endpoint: ACE  | No test item related histopathological effects in the high dose group.            |

**Lee et al.,  
2019**

TiO<sub>2</sub> NPs P25  
(15–24 nm).

OECD  
Guideline  
414 (Pre-  
natal  
Toxicity  
Study).

Test item:

Nanoparticles in  
deionised water.  
  
80/20  
anatase/rutile.

Mean diameter of  
approximately 21  
nm (minimum of  
100 particle sizes  
averaged)  
administered daily  
by oral gavage.

Dosage:

Test item was  
administered from  
Gestational Days  
6 to 19 at dose  
levels of 0, 100,  
  
300 and 1000  
mg/kg with a dose  
volume of 10  
mL/kg.

Sprague–Dawley  
rats (12 females  
per group).

Quantitative  
analysis in  
blood/tissues.

Four groups of  
twelve females  
per group in the  
toxicology

group (total test  
animals: 48)  
and four groups  
of four females  
in the tissue  
distribution  
group (total test  
animals: 16).

No statistically  
significant  
differences  
general clinical  
signs, body  
weight, organ  
weights  
(absolute and  
relative to  
weight),  
macroscopic  
findings except  
statistically  
significant  
decrease in  
intake but  
correlated  
decreased  
weight or body  
weight gain  
during the  
period of the  
females of  
high-dose  
No statistically  
significant  
differences  
caesarean  
section  
parameter  
fetal external  
and visceral  
examination  
  
A small but  
statistically  
significant  
increase (4%)  
was observed  
the number of  
ossification  
centres in the  
metatarsals

# Immunotoxicity

| Reference | TiO2<br>characterisation | Quality of<br>study<br>e.g.,<br>OECD/GLP | Method and<br>duration of<br>dosing | Study<br>methodology<br>to include<br>species,<br>numbers,<br>controls, | Results |
|-----------|--------------------------|--|-------------------------------------|---|---------|
|-----------|--------------------------|--|-------------------------------------|---|---------|

Statistically significant decreases in CSF plasma levels (~30% in females) and plasma IgM (~12% in females and in males) were observed at the highest dose compared to controls.

E171 accumulation in the stomach of several rats administered 1,000 mg/kg E171 for 90 days.

Ti concentrations increased in colons of both sexes administered 1,000 mg/kg E171 compared with the control while colonic superoxide dismutases (SOD)-1 (male and female) SOD-2 (female) protein levels were down-regulated.

When exposed to AGS cells

E171 suspended in distilled water, sonicated for at least 10 minutes.

E171 administered by oral gavage at doses of 0, 10, 100 or 1,000 mg/kg bw/d for 90 days.

Quantitative analysis in Sprague-Dawley rat's

Sprague-Dawley rats (10/sex/group) were administered E171 by oral gavage at doses of 0, 10, 100 or 1,000 mg/kg bw/d for 90 days.

Ti concentrations were measured in the colons, kidneys, and spleens harvested from

Study conducted according to OECD TG 408.

**Han et al. , 2020**

E171, anatase, 150 nm, 99.5% purity.



**NCI,  
1979**

[TR-097: Titanium Dioxide \(CASRN 13463-67-7\) \(nih.gov\)](#)

N/A

Titanium dioxide anatase.

Purity: 98%.

Groups of 50 rats of each sex and 50 mice of each sex were administered titanium dioxide in the diet at one of two doses, either 25,000 or 50,000 ppm, for 103 weeks and then observed for 1 additional week. Matched controls consisted of 50 untreated rats of each sex and 50 untreated mice of each sex. All surviving rats and mice were killed at 104 weeks.

Administration of the titanium dioxide had no appreciable effect on the mean body weights of rats or mice of either sex. With the exception of white feces, there was no other clinical sign that was judged to be related to the administration of titanium dioxide. Survival of the rats and the male mice at the end of the bioassay was not affected by the test chemical; mortality in female mice was dose related. Sufficient numbers of dosed and control rats and mice of each sex were at risk for development of late-appearing tumors.

In the male and female mice, tumours occurred in dosed groups. Incidences were significantly higher than those for corresponding control groups. It is concluded under the conditions of the bioassay, titanium dioxide was not carcinogenic by the oral route. Fischer 344 rats or B6C3F1 mice.

**Akagi et al., 2023 - 28 Day Study**

6 nm TiO<sub>2</sub> nanoparticles.

N/A

5 female and 5 male F344/DuCrI CrIj rats.

TiO<sub>2</sub> NPs with a crystallite size of 6 nm were examined in male and female F344/DuCrI CrIj rats by repeated oral administration of 10, 100, and 1000 mg/kg bw/day (5/sex/group) for 28 days.

No mortality observed in any group, and no treatment-related adverse effects were observed in body weight, urinalysis, haematology, serum biochemistry, organ weights, and histopathology examination. Histopathology examination revealed TiO<sub>2</sub> particles as yellowish-brown deposits of extracellular material. The particles observed in the gastrointestinal lumen were also found in the nasal cavity, epithelium, and stromal tissue. The 28-day study. Overall, no effects were observed after repeated oral administration of TiO<sub>2</sub> with a crystallite size of 6 nm at up to 1000 mg/kg bw/day regarding general toxicology.

**Akagi et al., 2023 - 90 Day Study**

6 nm TiO<sub>2</sub> nanoparticles.

N/A

10 female and 10 male F344/DuCrI CrIj rats.

TiO<sub>2</sub> NPs with a crystallite size of 6 nm were examined in male and female F344/DuCrI CrIj rats by repeated oral administration of 100, 300, and 1000 mg/kg bw/day (10/sex/group) for 90 days.

No mortality observed in any group, and no treatment-related adverse effects were observed in body weight, urinalysis, haematology, serum biochemistry, organ weights. In addition, the following lesions were observed: Peyer's patches in the ileum, cervical lymph nodes, mediastinal lymph nodes, bronchus-associated lymphoid tissue, and trachea. The 90-day study. Overall, no effects were observed after repeated oral administration of TiO<sub>2</sub> with a crystallite size of 6 nm at up to 1000 mg/kg bw/day regarding general toxicity, accumulation of titanium in the liver, kidneys,

|              |                           |  |   |   |
|--------------|---------------------------|--|---|---|
| Pinget et al | E171, anatase, 30-300 nm. | N/A  | Male C67BL/6J Ausb mice were exposed to E171 via drinking water at doses of either 0, 2, 10, or 50 mg TiO <sub>2</sub> /kg BW/day for 3 weeks to determine impact on colonic microbiota composition and on gut bacterial metabolites (10 mice/group).   | At the highest dose tested, TiO <sub>2</sub> had minimal impact on the composition of the gut microbiota. Alterations in bacterial metabolites were observed from 10 mg/kg bw/d.                |
|              |                           |  |   |   |
| Pinget et al | E171 was                  | Mice were exposure to E171 via drinking water for 4 weeks at doses of 0, 2, 10, 50 mg/kg bw/d. Dose is calculated based on water intake measured per cage. | Incubated commensal bacteria derived from mouse colons anaerobically for 5 days with dose of 0, 2, 10, 50 µg/ml of TiO <sub>2</sub> biofilm formation (6 mice/group). Impact of TiO <sub>2</sub> on colonic epithelial function was determined by comparison of gene expression of key markers Muc2, Tjp1, Defb3, and Gzmb in colonic | Doses of 10 and 50 µg/ml TiO <sub>2</sub> significantly promoted biofilm formation by commensal bacteria. There was reduced expression of colonic mucin gene, a key component of the intestinal |
|              |                           |  |   |   |
| Pinget et al | E171 was                  | Microbiota populations in  |   |   |
|              |                           |  |   |   |

# Neurotoxicity

| Reference | TiO2 characterisation | Quality of study e.g., OECD/GLP | Method and duration of dosing | Study methodology to include species, numbers, controls, | Res |
|-----------|-----------------------|---------------------------------|-------------------------------|--|-----|
|-----------|-----------------------|---------------------------------|-------------------------------|--|-----|

**Sofranko  
et al.,  
2021**

10 mg/g TiO<sub>2</sub>, 2  
mg/g  
polyvinylpyrrolidone-  
coated Ag.

OECD 424  
Neurotoxicity  
study in the  
rodents.

N/A

10 female and 10  
male C57BL/6J mice.

The mice were fed  
ad libitum with food  
pellets dosed with  
10 mg/g TiO<sub>2</sub>, 2  
mg/g  
polyvinylpyrrolidone-  
coated Ag or control  
pellets for 28 days.

The  
TiO<sub>2</sub>  
appl  
pelle  
fema  
mice  
expo  
or w  
post  
reco

No m  
neur  
chan  
neur  
biocl  
imm  
anal  
obse  
beha  
in an  
cogn  
abse  
the A  
mice  
perfo  
were

the m  
diffe  
sex  
mice  
expo  
28 d  
cons  
moto  
and  
corti  
spec  
kina  
Fem  
were  
inve

**Grissa et al. (2016)**

TiO<sub>2</sub> NPs, anatase, 5–12 nm (TEM, XRD). N/A

Internal exposure: quantitative in male Wistar rat tissues; methodology with important flaws. N/A

Ther  
stati  
signi  
relat  
the l  
and  
per o  
grou  
a sta  
signi  
relat  
brain  
mg/k  
TiO<sub>2</sub>

**Gerber et al., 2022**

TiO<sub>2</sub> NPs, average primary particle size of 26.2 ± 10.7 nm. N/A

N/A

The aim of the study was to investigate the effects of two common types of NP,

Titanium dioxide NP (TiO<sub>2</sub> NP) and silver NP (AgNP), on neuronal function following acute (0.5 h), sub-chronic (24 h and 48 h) and chronic (14 days) exposure in vitro rat cortical cells.

Acut  
chro  
TiO<sub>2</sub>  
effec  
chro  
only  
redu  
func  
affec  
morp

**Ciu et al.,  
2021**

TiO<sub>2</sub> NPs.

N/A

36 male  
Sprague Dawley  
rats aged  
postnatal day  
21 (PND 21)  
were injected N/A  
intraperitoneally  
with TiO<sub>2</sub> NPs  
(20 mg/kg)  
and/or BEO (200  
mg/kg).

**Naima et  
al., 2021**

TiO<sub>2</sub> NPs.

N/A

Rats were  
injected  
intravenously  
with a single  
dose of TiO<sub>2</sub>-  
NPs (20 mg/kg  
body weight)  
and were N/A  
subjected to  
cognitive and  
emotional tests  
using Morris  
water maze and  
elevated plus  
maze.

TiO<sub>2</sub>  
durin  
perio  
anxi  
beha  
impa  
neur  
and  
dam  
hipp  
BEO  
signi  
ame  
neur  
by T  
expo

Acut  
injec  
impa  
perf  
throu  
biocl  
struc  
and  
shou  
their  
addi  
appl



**Canli et al., 2020**

TiO<sub>2</sub> NPs

N/A

Oral administration of TiO<sub>2</sub> for 14 days (0, 0.5, 5, and 50 mg/kg bw/day).

Female rats.

Resu  
brain  
decr  
treat  
ATPa  
incre

Intes  
ATPa  
show  
chan

Leve  
show  
chan  
TBAF  
high  
show  
decr

TiO<sub>2</sub>  
accu  
(dos  
in tis

The  
to be  
sens  
again  
TiO<sub>2</sub>